Feed

Nearly 90% of women called back after a suspicious mammogram do not have breast cancer, yet false positives lead to unnecessary biopsies, psychological distress, additional healthcare visits, and significant financial costs. The authors present an in-clinic compression device compatible with commercial ultrasound systems, utilizing Sub-Hertz Analysis of Visco-Elasticity (SAVE) to assess tissue viscoelasticity as a biomarker for malignancy. SAVE combines ultrasound imaging with a computer-controlled axial compression device to measure viscoelastic parameters, improving diagnostic accuracy and reducing subjectivity. The device integrates mechanical, electrical, and software components into a user-friendly tool, automating the SAVE method. Initial tests with breast phantoms showed strong agreement with a standard mechanical testing instrument, demonstrating high accuracy in key parameters such as the primary time constant, T₁ (mean absolute error: 5.78%). These results underscore the device's potential for accurate measurement of viscoelastic parameters of tissue with the goal of characterizing breast masses in vivo.Clinical Relevance- This novel compression device, facilitates the accurate application of SAVE method for in-clinic breast lesion assessment, aiming to improve specificity and reduces false positives. Its integration with standard ultrasound systems provides a cost-effective, non-invasive method to distinguish benign from malignant lesions, reducing unnecessary biopsies and patient anxiety. This advancement has the potential to enhance diagnostic workflows and patient care.